• Users Online: 221
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2020| July-December  | Volume 6 | Issue 2  
    Online since December 28, 2020

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
Dramatic response to metronidazole in a patient with pemphigus foliaceus
Ahu Yorulmaz, Basak Yalcin, Emine Tamer, Merve Cansu Kaya, Beyza Koca
July-December 2020, 6(2):99-101
  1 2,029 52
Isotretinoin: In acne and beyond – An overview
Aditya Kumar Bubna
July-December 2020, 6(2):59-69
Isotretinoin (ISO) has proven to be an extremely valuable drug for all dermatologists. Since its approval in 1982 by the US Food and Drug Administration for nodulocystic acne, it still remains the gold standard drug for the above indication till date, facing no competition from its contemporaries. Along with the treatment of nodulocystic acne, ISO has proved valuable in several other dermatoses as well. Further, even for treating acne, there have been a number of modifications as far as the prescription of ISO is concerned. This review will briefly highlight the various aspects of isotretinoin for acne and other cutaneous disorders.
  1 8,501 293
Safety and efficacy of one week oral steroid therapy in the treatment of common eczemas: An open label randomized controlled pilot study
Vikrant Abhay Saoji, Arun L Bhat
July-December 2020, 6(2):81-84
Introduction: Oral steroids are not commonly used because of fear of side effects. A study was conducted to find out if a short course of 1 week of oral steroid without tapering is effective and safe for the treatment of common eczemas. Materials and Methods: Patients with common eczemas were included in the study. There were five groups. One group each received tablet prednisolone 15 mg morning and 10 mg after dinner for 7 days, tablet methylprednisolone 16 mg morning and 8 mg night for 7 days, and tablet betamethasone 2 mg morning and 1 mg night for 7 days. One group received tablet betamethasone 3 mg once a day as a single morning dose for 7 days and the last group received tablet deflazacort 18 mg morning and 12 mg night for 7 days only. All the patients also received topical clobetasol propionate cream for 1 month. However, the maximum permissible amount of topical clobetasol propionate was 30 g in a month. Basal serum cortisol at 8 am along with ACTH stimulation test was carried out in all the patients on day 10th. The tests were repeated on 30th day if negative on day 10th. Results: In all groups, rapid improvement was seen at visit 2, which further continued at visit 3. No suppressive effect on hypothalamic–pituitary–adrenal (HPA) axis was seen. Conclusion: A short course of oral steroid of 25 mg of prednisolone equivalent for a period of 7 days was found to be effective and safe, and 7 days of oral steroids do not need tapering.
  - 4,399 100
Myriads of cutaneous manifestations with Nilotinib, treated by acitretin – a case report
Amrita A Hongal, TN Revathi, Seetharampura Ramamurthy Radhika, Kanathur Shilpa
July-December 2020, 6(2):85-87
A remarkable advancement is been made in the treatment of cancer, through chemotherapeutic drugs like tyrosine kinase inhibitors (TKI), etc. Chemotherapy induced cutaneous side effects are multiple and usually they are underreported. Nilotinib is a second generation TKI, which is approved for imatinib resistant CML. Various cutaneous and its appendageal changes have been noticed with the use of nilotinib usage. Here, we report such case of a 34 year old male, who is a case of CML being treated with Nilotinib for 2.5 years, presented to us with perforating folliculitis, psoriasiform dermatosis, KP like lesions, madarosis and textural changes of scalp hair.
  - 2,041 70
Response to intravenous immunoglobulin in a patient of drug reaction eosinophilia systemic symptom syndrome with renal involvement complicated by steroid-induced avascular necrosis of femur
Suman Patra, Richa Rupla, Saumya Narula, Dinesh P Asati
July-December 2020, 6(2):88-90
Drug reaction eosinophilia systemic symptom (DRESS) is one of the most serious adverse drug reactions and corticosteroid is the mainstay of management. Here, we report a case of DRESS with renal involvement complicated by steroid-induced avascular necrosis of femur. The patient responded significantly with two courses of intravenous immunoglobulin given at monthly interval, and his corticosteroid dose could be tapered early.
  - 1,619 32
Successful treatment of an uncommon disorder: Letterer-siwe disease
Bhagyashree Babanrao Supekar, Tejal Devidas Ghanate, Vaishali H Wankhade, Rajesh Pratap Singh
July-December 2020, 6(2):91-93
  - 1,368 46
Efficacy and safety of a sustained-release preparation of pregabalin in chronic pruritus
Manju Meena, Kapil Vyas, Manisha Balai, Ashok Kumar Khare, Lalit Kumar Gupta, Asit Mittal
July-December 2020, 6(2):93-95
  - 1,570 44
Multiple epidermoid cysts in a renal transplant patient taking tacrolimus
Anup Kumar Tiwary
July-December 2020, 6(2):96-97
  - 1,460 31
Erythema gyratum repens responding to isotretinoin
Palvi Singla, Sukhjot Kaur, Sunil Kumar Gupta
July-December 2020, 6(2):97-99
  - 1,531 39
News from regulatory corner: Safety communication and recent drug approvals
Manasi Shirolikar
July-December 2020, 6(2):101-102
  - 1,319 43
A pilot study to assess the effectiveness of local application of salbutamol and nitroglycerine for improvement of hand dexterity and comfort in extreme cold climate at high altitude
Surinderpal Singh, Gautam Kumar Singh, Atul Kotwal, Latika Mohan, Rajan Grewal
July-December 2020, 6(2):70-75
Background: Reduced manual dexterity and hand comfort affect all people exposed to extreme cold. Ointment nitroglycerine 0.2% (NTG) and ointment salbutamol 0.5% (Sal) applied topically to the extremities could result in increased local blood flow and temperature, improving hand comfort and dexterity in extreme cold. Aim and Objectives: This study was designed to elucidate if the application of NTG or Sal would improve manual dexterity and hand comfort in extreme cold conditions. Materials and Methods: A double-blind, randomized controlled trial was conducted at 3500 m altitude in 105 individuals divided into three equal-sized groups. Group A received NTG, Group B placebo (white soft paraffin), and Group C Sal, for application to the extremities twice daily, for 2 weeks. Hand skin temperatures (Tsk), Pegboard scores, and a Graphic Rating Scale (GRS) for pain were compared before and after the intervention. Adverse effects and user acceptability criteria were recorded. Results: Participants of all three groups showed significant improvement in Tsk, Pegboard scores, and GRS scores postintervention, however none of the parameters were different between groups. The acceptability questionnaire scores were best in the placebo group. Conclusion: Neither NTG nor Sal was superior to placebo for improvement in hand comfort or dexterity, in extreme cold at high altitude.
  - 2,389 72
An open-label, prospective, comparative, double-arm clinical trial to evaluate the safety and effectiveness of minocycline extended-release formulation compared with minocycline immediate-release formulation in the management of patients with papulopustular acne
Sushil Pande, Gaurav Deshmukh, Dhiraj Dhoot, Nilesh Andhorikar
July-December 2020, 6(2):76-80
Introduction: Minocycline because of its multiple advantages is considered as first-line therapy in the management of acne. However, conventional formulations of minocycline are associated with multiple side effects, thus limiting its use. Thus, extended-release formulation of minocycline was developed. Materials and Methods: This was an open-label, prospective, interventional, comparative, double-arm study. Patients with papulopustular acne were either received minocycline extended release (ER) 1 mg/kg/day or minocycline immediate release (IR) 100 mg/day for a period of 8 weeks. Safety was assessed by analyzing the adverse event (AE) profile in both the groups. Effectiveness was assessed by analyzing improvement in the mean inflammatory lesion count. Results: A total of 100 patients were included in the study, 50 in each group. A total of four AEs were reported by 2 (4.0%) patients in the ER group, whereas ten AEs were reported by 5 (10.0%) patients in the IR group. The mean inflammatory lesion count in the ER group at baseline was 14.95 ± 3.76, whereas in the IR group, it was 14.52 ± 3.38. Significant decrease in inflammatory lesion count was observed in both the groups during treatment period. Conclusion: The results of this study prove that ER formulation of minocycline is associated with better improvement in acne compared to IR formulation. The study also proves that ER formulation is associated with better safety profile compared to IR profile.
  - 3,942 101